Robert J. Gould - 13 Jan 2023 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role
Interim President & CEO, Director
Signature
/s/ Greg Tourangeau, as attorney-in-fact for Robert J. Gould
Issuer symbol
FULC
Transactions as of
13 Jan 2023
Transactions value $
-$101,490
Form type
4
Filing time
13 Jan 2023, 17:33:36 UTC
Previous filing
29 Jun 2022
Next filing
29 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FULC Common Stock Sale -$101,490 -6,766 -1.3% $15 499,864 13 Jan 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022.